SuperworthProtagonist Therapeutics free cash flow PTGX
Cash from operations less capital spending, by quarter and over the last twelve months, from 2015.
- Last 12 months, to Jun 30, 2026
- $130.6M
- Latest quarter, Q2 FY26
- $218.9M
- Fiscal year 2025
- $56.1M
- −69% on the year before
Protagonist Therapeutics' free cash flow was $130.6M over the twelve months to Jun 30, 2026, up 252% on a year earlier.
In its latest quarter, Q2 FY26, it was $218.9M.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2025 | $56.1M | −69% |
| FY2024 | $182.8M | n/a |
| FY2023 | −$70.8M | n/a |
| FY2022 | −$108.9M | n/a |
| FY2021 | −$109M | n/a |
| FY2020 | −$73M | n/a |
| FY2019 | −$42.5M | n/a |
| FY2018 | −$50.4M | −1673% |
| FY2017 | $3.2M | n/a |
| FY2016 | −$30.3M | n/a |
| FY2015 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $218.9M | n/a | $130.6M | |
| Q1 FY26 | −$49.2M | −139% | −$117.9M | |
| Q4 FY25 | −$37.1M | n/a | $56.1M | |
| Q3 FY25 | −$2M | n/a | $63.7M | |
| Q2 FY25 | −$29.6M | −111% | $37.1M | |
| Q1 FY25 | $124.8M | n/a | $335.3M | |
| Q4 FY24 | −$29.5M | −274% | $182.8M | |
| Q3 FY24 | −$28.6M | n/a | $229.2M | |
| Q2 FY24 | $268.6M | n/a | $230.8M | |
| Q1 FY24 | −$27.7M | n/a | −$64.2M | |
| Q4 FY23 | $16.9M | n/a | −$70.8M | |
| Q3 FY23 | −$27M | n/a | −$119.5M |
Against its peers
Companies in Drug Manufacturers - General nearest Protagonist Therapeutics' size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| PTGXProtagonist Therapeutics | 1.5% |
| CORTCorcept Therapeutics | 1.2% |
| TGTXTG Therapeutics | 0.2% |
| BMRNBiomarin Pharmaceutical | 6.8% |
| ALKSAlkermes plc. | 3.0% |
| AMRXAmneal Pharmaceuticals | 2.0% |
| LGNDLigand Pharmaceuticals | 2.2% |
| KNSAKiniksa Pharmaceuticals International | 3.1% |
| JAZZJazz Pharmaceuticals | 11.5% |
| INDVIndivior Pharmaceuticals | −2.7% |
| ARQTArcutis Biotherapeutics | 1.0% |
| Peer median | 2.1% |
Where Protagonist Therapeutics ranks
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Protagonist Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.